// App-Quantinova.ai

650 : Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Nirali N Shah

Principal Investigators

  • Maryalice Stetler-Stevenson

  • Constance M. Yuan

  • Haneen Shalabi

  • Bonnie Yates

  • Cindy Delbrook

  • Ling Zhang

  • Daniel W. Lee III

  • David Stroncek

  • Crystal L. Mackall

  • Terry J Fry

Medical Centers

  • Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Virginia, Charlottesville, VA

  • Laboraory of Pathology, National Cancer Institute, Gaithersburg, MD

  • Department of Medicine, Stanford University, Stanford, CA

  • Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

  • Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Cytokine release syndrome

Biomarkers

  • Breakpoint Cluster Region

  • Twist-related protein 1

  • Cerebrospinal fluid

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved